Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Slides:

Advertisements

Similar presentations

Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.

Advertisements

HIV Situation in India Dr Sunil Gaikwad.

ARV failure and resistance for the paediatrician

Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.

PrEP – New Drugs and Delivery Systems Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell.

Pre Test !!!!!!. How many classes of HIV meds are currently available?

ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified

 After completing this session the participant should be able to:  Discuss the goals of HIV treatment.  Understand when resistance testing should be.

HIV Care 2010: The 3 rd Revolution in HIV treatment Chris Farnitano, MD Noon Conference February 11, 2010.

Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to Patients Needs and Ensures Both.

Track B Workshop Controversies in the Management of HIV-positive Adults: A Case-Based Approach Sasisopin Kiertiburanakul, MD, MHS Associate Professor Department.

Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.

Presented by: Siti Rohaizah bt Othman. Arv DRUGS AVAILABLE IN UMMC Combivir (Lamivudine + Zidovudine) Stocrin (Efavirenz 600mg) Kaletra (Lopinavir 200mg.

ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.

Antiretroviral Drugs in Pregnancy and Breastfeeding: Importance of Surveillance and Implications for Developing Countries Lynne M. Mofenson, M.D. Pediatric,

PRINCIPLES OF ART IN TANZANIA

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD. Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants  Considerations for choice of ARV drugs.

Improving Adherence With Simplified HAART Regimens Improving Clinical Outcomes in HIV Patients.

Understanding mucosal immunity and HIV transmission: the way to new prevention technologies Robin Shattock Centre for Infection, Division of Cellular &

HIV Therapy Experience is the Best Teacher David K. Stein, M.D. Director, Adult HIV Research Activities Jacobi Medical Center Associate Professor of Clinical.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.

Medicines Patent Pool and Seychelles A primer For more information visit:

WHO - PSM 14/7/2005 Principles for selection of medicines Dr Mary R. Couper Quality Assurance and Safety of Medicines WHO.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere February 2006.

Current and Future Trends in HIV Therapy Hail M. Al-Abdely Consultant, Infectious Diseases.

1 HIV Drugs, Updates, & the Hope for Entry Inhibitors Kent Williams Doctor of Pharmacy Candidate 2011 Wingate University School of Pharmacy Saturday, February.

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.

AIDS ΘΕΡΑΠΕΙΑ Κατευθυντήριες Οδηγίες ΓΕΩΡΓΙΟΣ ΠΑΝΟΣ BSc(Biomed.Eng.), CEng, MIET, MD, PhD, DTM&H(Lon), FRCP Αν. Καθηγητής Παθολογίας & Λοιμωδών Νοσημάτων.

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

AN OVERVIEW OF PHARMACOVIGILANCE OF HIV/AIDS IN NIGERIA

Side effects of antiretroviral drugs

Retrovirus HIV (humans) Animal viruses resulting in cancer / AIDS 15-39%

© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.

Antiretroviral Therapy (ART)

Choosing Among Current Antiretroviral Regimens: The Relevance of Drug–Drug Interactions and Barrier to Resistance This program is supported by an independent.

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

Anti-Retroviral Therapy-considerations and resistance management

Giới thiệu về điều trị ARV

Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive.

Antiviral Drugs Chapter 45.

M. Colafigli, C. Torti, E. M. Trecarichi, L. Albini, A. Rosi, V

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class S. Monge, V.

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

Drug-resistant human immunodefiency virus

Results of round 1 of the Delphi survey

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine K. Theys, R.J. Camacho,

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

Combating Susceptibility to Drug Resistance

Forecasting for ARVs medicines

G. Rocheleau, C.J. Brumme, J. Shoveller, V.D. Lima, P.R. Harrigan

F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E

Volume 42, Issue 3, Pages (March 2005)

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009 S. Di Giambenedetto, M. Prosperi, I.

M. Aires-de-Sousa Clinical Microbiology and Infection

Systematic review of antibiotic consumption in acute care hospitals

Antiretroviral therapy and its complications

CASO CLINICO Il paziente naϊve con resistenze al basale.

J.L. Balcázar Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy M. Franzetti, M.

Figure 1. Rate of PDR in infants according to ARV exposure

Tertiary structures of HIV-1 reverse transcriptase and chemical formulas of NRTIs and NNRTIs. (A) HIV-1 RT complexed with dsDNA and zidovudine triphosphate.

Combating Susceptibility to Drug Resistance

Presentation transcript:

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses P. Rojas Sánchez, M. de Mulder, E. Fernandez-Cooke, L. Prieto, P. Rojo, S. Jiménez de Ory, M. José Mellado, M. Navarro, J. Tomas Ramos, Á. Holguín Clinical Microbiology and Infection Volume 21, Issue 6, Pages 605.e1-605.e9 (June 2015) DOI: 10.1016/j.cmi.2015.02.003 Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 DRM prevalence across ARV families and rate of patients with predicted susceptibility to each ARV in the 48 HIV-1 infected patients when TC-DRM was first detected. DRM, drug resistance mutation; ARV, antiretroviral. DRM and predicted susceptibility levels to each ARV drug according to the Stanford HIVdb algorithm. 3TC, lamivudine; ATV, atazanavir, NFV, nelfinavir; AZT, zidovudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; ETV, etravirine; FPV, fosamprenavir; FTC, emtricitabine; ABC, abacavir; IDV, indinavir; LPV, lopinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor. d4T, stavudine; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir; TPV, tipranavir. Clinical Microbiology and Infection 2015 21, 605.e1-605.e9DOI: (10.1016/j.cmi.2015.02.003) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 ARV susceptibility among 48 HIV-1 infected patients when triple resistance was first detected. Color code: green, susceptible; blue, low-level resistance; yellow, intermediate resistance; red, high-level resistance. The percentage shows susceptibility to ARV drugs among 48 patients predicted by Stanford's HIVdb algorithm. 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; ETV, etravirine; FPV, fosamprenavir; FTC, emtricitabine; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor. d4T,stavudine; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir; TPV, tipranavir. Clinical Microbiology and Infection 2015 21, 605.e1-605.e9DOI: (10.1016/j.cmi.2015.02.003) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 ARV susceptibility among 48 HIV-1 infected patients when triple resistance was first detected. Color code: green, susceptible; blue, low-level resistance; yellow, intermediate resistance; red, high-level resistance. The percentage shows susceptibility to ARV drugs among 48 patients predicted by Stanford's HIVdb algorithm. 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; ETV, etravirine; FPV, fosamprenavir; FTC, emtricitabine; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor. d4T,stavudine; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir; TPV, tipranavir. Clinical Microbiology and Infection 2015 21, 605.e1-605.e9DOI: (10.1016/j.cmi.2015.02.003) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions